ICU Medical (NASDAQ:ICUI – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.950-5.350 for the period, compared to the consensus earnings per share estimate of 4.830. The company issued revenue guidance of -.
ICU Medical Stock Performance
Shares of ICUI traded down $1.89 on Wednesday, reaching $121.79. 301,882 shares of the stock traded hands, compared to its average volume of 275,420. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of -50.22 and a beta of 0.69. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.61 and a quick ratio of 1.09. ICU Medical has a 12 month low of $78.28 and a 12 month high of $160.00. The stock’s 50-day moving average price is $118.94 and its 200-day moving average price is $107.22.
ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.06. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. The firm had revenue of $566.66 million for the quarter, compared to analysts’ expectations of $553.15 million. Equities analysts forecast that ICU Medical will post 3.5 EPS for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on ICUI
Insider Transactions at ICU Medical
In related news, Director Elisha W. Finney sold 300 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $104.95, for a total transaction of $31,485.00. Following the completion of the transaction, the director now directly owns 2,129 shares in the company, valued at $223,438.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, COO Christian B. Voigtlander sold 12,539 shares of ICU Medical stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $103.95, for a total transaction of $1,303,429.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elisha W. Finney sold 300 shares of ICU Medical stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $104.95, for a total value of $31,485.00. Following the sale, the director now directly owns 2,129 shares of the company’s stock, valued at $223,438.55. The disclosure for this sale can be found here. Insiders have sold a total of 14,839 shares of company stock valued at $1,546,014 over the last 90 days. 6.70% of the stock is owned by company insiders.
About ICU Medical
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Stories
- Five stocks we like better than ICU Medical
- What is a SEC Filing?
- What Are Bonds? A High-Level Overview
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- What Investors Need to Know About Upcoming IPOs
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.